Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Manhattan Associates Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.8 (market cap $6.04B), while Manhattan Associates Inc trades at $205.6 (market cap $12.06B). The key difference: Manhattan Associates Inc is the larger of the two by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Manhattan Associates Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Manhattan Associates Inc for 12 Days on average.
| IOVA | MANH | |
|---|---|---|
Market Cap | $6.04B | $12.06B |
Volume | 14,805,993 | 376,150 |
Sector | Health | Technology |
52-Week High | $14.82 | $223.76 |
52-Week Low | $1.81 | $120.88 |
Typical Hold Time | 0 Days | 12 Days |
Enterprise Value | $5.97B | $11.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MANH trades at $205.29, up 1.57% with strong technical momentum and bullish moving average signals. The company demonstrates robust profitability with 18.67% net margins and consistent earnings beats, though valuation metrics remain elevated. Recent news includes product expansion with Editions launch and ongoing legal investigations regarding fiduciary duties.
Outlook remains positive with analyst consensus at Buy and $210.50 target, though risks include high valuation multiples and legal scrutiny. The stock offers growth potential through strong operational performance but faces headwinds from potential governance concerns and competitive pressures in the software sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
